Main Street Group’s Viking Therapeutics VKTX Stock Holding History

Main Street Group’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10	Closed	-$553	–	862
2024 Q2	$553	Hold	10	–	–	﹤0.01%	792
2024 Q1	$795	Buy	+10	New	+$445	﹤0.01%	809

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Main Street Group's VKTX Position: Q3 2024 in Review

Main Street Group sold out of Viking Therapeutics (VKTX) in Q3 2024, closing a stake of 10 shares — an estimated $553 sold.

Main Street Group first reported a position in VKTX in Q1 2024 and held it in 2 quarters. The position peaked at $795 in Q1 2024. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

Main Street Group reported no remaining Viking Therapeutics position as of Q3 2024 after selling out during the quarter.
Main Street Group sold 10 Viking Therapeutics shares in Q3 2024, an estimated $553.
Main Street Group first reported a position in Viking Therapeutics in Q1 2024 and held it in 2 quarters.
Main Street Group's Viking Therapeutics position peaked at $795 in Q1 2024.
422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Main Street Group's 13F filing for Q3 2024, filed 13 Nov 2024.